Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-02
2007-01-02
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S008100, C530S322000, C536S007400
Reexamination Certificate
active
10616046
ABSTRACT:
The present invention relates (a) to new compounds represented by Formula I:wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, V represents an anti-inflammatory steroid or nonsteroid subunit, or an antineoplastic or antiviral subunit and L represents a linking group covalently linking M and V; (b) to their pharmacologically acceptable salts, prodrugs and solvates, (c) to processes and intermediates for their preparation, and (d) to their use in the treatment of inflammatory
eoplastic/viral diseases and conditions in humans and animals.
REFERENCES:
patent: 4474768 (1984-10-01), Bright
patent: 4710495 (1987-12-01), Bodor
patent: 5004731 (1991-04-01), Philippe et al.
patent: 5747467 (1998-05-01), Agouridas et al.
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6228346 (2001-05-01), Zhang et al.
patent: 6273086 (2001-08-01), Ohki et al.
patent: 6297260 (2001-10-01), Bandarage et al.
patent: 6402733 (2002-06-01), Daugherty
patent: 6566509 (2003-05-01), Griffin et al.
patent: 2001/0006962 (2001-07-01), Myhren et al.
patent: 2004/0005641 (2004-01-01), Burnet et al.
patent: 2004/0033969 (2004-02-01), Burnet et al.
patent: 2004/0087517 (2004-05-01), Burnet et al.
patent: 2004/0186063 (2004-09-01), Gutke et al.
patent: 0283055 (1990-08-01), None
patent: 0771564 (1997-05-01), None
patent: 0775489 (1997-05-01), None
patent: 0 283 055 (1998-09-01), None
patent: 00680967 (1998-10-01), None
patent: 0 895 999 (1999-02-01), None
patent: 0984019 (2000-03-01), None
patent: 0984019 (2000-03-01), None
patent: 1 046 394 (2000-10-01), None
patent: 2 327 084 (1999-01-01), None
patent: WO 94/13690 (1992-06-01), None
patent: WO 92/13872 (1992-08-01), None
patent: WO 92/13873 (1992-08-01), None
patent: WO 94/14834 (1994-07-01), None
patent: WO 97/41255 (1997-11-01), None
patent: WO-97/41255 (1997-11-01), None
patent: WO 98/56801 (1998-12-01), None
patent: WO-99/28308 (1999-06-01), None
patent: WO 99/51616 (1999-10-01), None
patent: WO-99/64040 (1999-12-01), None
patent: WO 00/42055 (2000-07-01), None
patent: WO-00/64882 (2000-11-01), None
patent: WO-02/15700 (2002-02-01), None
patent: WO-02/055531 (2002-07-01), None
patent: WO-03/070173 (2003-08-01), None
patent: WO-03/070174 (2003-08-01), None
patent: WO-03/070254 (2003-08-01), None
Burnet et al., “Conjugates of biologically active compounds, methods for their preparation and use, formulation, and pharmaceutical applications thereof,” U.S. Appl. No. 60/357,789, filed Feb. 15, 2002.
Brandt-Rauf et al., “Fluorescent Assay For Estimating the Binding of Erythromycin Derivatives to Ribosomes,” Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, D.C., 14(1):88-94. (1978).
Gladue R. P. et al.,“In Vitro and In Vivo Uptake of Azithromycin (CP-62,993) by Phagocytic Cells: Possible Mechanism of Delivery and Release at Sites of Infection,”Antimicrob. Agents and Chemother.,33. 1989, 277-282.
Olsen K. M. et al., “Intrapulmonary Pharmacokinetics of Zithromycin in Healthy Volunteers Given Five Oral Doses,”Antimicrob. Agents and Chemother.,40, 1996, 2582-2585.
Mikasa, K. et al., “The anti-inflammatory effect of erythromycin in zymosan-induced peritonitis of mice,”J. Antimicrob. Chemother.,30, 1992, 339-348.
“Discussion, Genomic organization of axolotl 1g genes,”J. Immunol.,159, 1997, 3395-4005.
Takizawa, H. et al., “Erythromycin Modulates IL-8 Expression in Normal and Inflamed Human Bronchial Epithelial Cells,”Am. J. Respir. Crit. Care Med.,156, 1997, 266-271.
Labro, M.T., “Anti-inflammatory activity of macrolides: a new therapeutic potential?”J. Antimicrob. Chemother.41, 1998, 37-46.
Cazzola, M., et al., “Potential role of macrolides in the treatment of asthma,”Mondaldi Arch. Chest Dis.,55, 2000, 231-236.
Avila, P.C. et al., “Macrolides, asthma, inflammation, and infection,”Ann. Allergy Asthma Immunol,84, 2000, 565-568.
Amayasu, H. et al., “Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma,”Ann. Allergy, Asthma&Immunol,84, 2000, 594-598.
Shoji, T. et al., “Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma,”Clin. Exp. Allergy,29, 999, 950-956.
Griffith, E.C., et al., “Yeast Three-Hybrid System for Detecting Ligand-Receptor Interactions,”Methods in Enzymology,328m 2000, 89-110.
Denis A. et al., “Synthesis and Antibacterial Activity of HMR 36K47 , A New Ketolide Highly Potent Against Erythromycin-Resistant and Susceptible Pathogens,”Bioorg.&Med. Chem. Lett,9, 1999, 3075-3080.
Agouridas C. et al., “Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent against Macrolide-Resistant and -Susceptible Respiratory Pathogens,”J. Med. Chem.,41, 1998, 4080-4100.
Sun, Or Y. et al.J. Med. Chem.2000, 43, 1045-1049.
McFarland, J. W. et al., “Repromicin Derivatives with Potent Antibacterial Activity againstPasteurella multocida,”J. Med. Chem.,50, 1997, 1041-1045.
Denis A. et al., Synthesis of 6-O-Methyl-Azithromycin and Its Ketolide Analogue via Beckmann Rearrangement of 9(E)-6-O-Methyl-Erythromycin Oxime,Bioorg.&Med. Chem. Lett.,8, 1998, 2427-2432.
Lartey et al., “Synthesis of 4”-Deoxy Motilides: Identification of a Potent and Orally Active Prokinetic Drug Candidate,J. Med. Chem.,38, 1998, 1793-1798.
Kirst, H.A. et al., “34. Metabolism of macrolides,” Bryskier, A. J. et al., Ed.Macrolides, Chemistry, Pharmacology and Clinical Use; Bryskier, Amette Blackwell: Paris, 1993; pp. 485-491.
Ma, Z. et al., “Discovery and Development of Ketolides as a New Generation of Macrolide Antimicrobial Agents,”Current Medicinal Chemistry—Anti-Infective Agents,1, 2002, 15-34.
Pascual A. et al., “Uptake and intracellular activity of ketolide HMR 3647 in human phagocytic and non-phagocytic cells,”Clin. Microbiol. Infect.,7, 2001, 65-69.
Hand, W. L. et al., “Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes,”Int. J. Antimicrob. Agents,18, 2001, 419-425.
Amsden, G. W., “Advanced-generation macrolides: tissue-directed antibiotics,”Int. J. Antimicrob. Agents,18, 2001, 11-15.
Johnson, J. D. et al., “Antibiotic uptake by alveolar macrophages,”J. Lab. Clin. Med.,95, 1980, 429-439.
Wildfeuer, A. et al., “Uptake of Azithromycin by Various Cells and Its Intracellular Activity under in Vivo Conditions,”Antimicrob. Agents Chemother.,40, 1996, 75-79.
Scorneaux, B. et al., “Intracellular Accumulation, Subcellular Distribution, and Efflux of Tilmicosin in Chicken Phagocytes,”Poult. Sci.,77, 1998, 1510-1521.
Mtairag, E. M. et al., “Investigation of dirithromycin and erythromyclamine uptake by human neutrophilsin vitro,”J. Antimicrob. Chemother.33, 1994, 523-536.
Anderson R. et al., “An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent,”J. Antimicrob. Chemother.,22, 1988, 923-933.
Tasaka, Y. et al., “Rokitamycin Uptake by Alveolar Macrophages,”Jpn. J. Antibiot.41, 1988, 836-840.
Harf, R. et al., “Spiramycin uptake by alveolar macrophages,”J. Antimicrob. Chemother.,22, 1988, 135-140.
Suzuki, T. et al., “General and facile method for determination of configuration of steroid-17-yl-methyl glycolates at C-20 based on kinetic examination,”Chem. Soc.,Perkin Trans. 1, 1998, 3831-3836.
McLean, H.M. et al., “Novel Fluorinated Antiinflammatory Steroid with Reduced Side Effects: Methyl 9α-Fluoroprednisolone-16-carboxylate,”J. Pharm. Sci.1994, 83, 476-480.
Little, R.J. et al., “Soft Drugs Based on H
Markovic Stribor
Mercep Mladen
Mesic Milan
Tomaskovic Linda
Darby & Darby
GlaxoSmithKline istrazivacki centar Zagreb
Peselev Elli
LandOfFree
Compounds, compositions as carriers for steroid/nonsteroid... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions as carriers for steroid/nonsteroid..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions as carriers for steroid/nonsteroid... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3764009